Nkarta Presents Preclinical Data Exploring Gene Knockout Strategies and Combination Agents with NK Cell-Based Therapies at the 2023 AACR Annual Meeting
April 17, 2023 17:01 ET
|
Nkarta, Inc.
Improved ADCC with ADAM17 gene knockout of NK or CAR NK cells, supporting ADAM17 KO use for clinical applications Increased specific killing of cancer cells in vitro by the combination of NKX101 and...
Nkarta to Participate at Upcoming Investor Conferences
April 12, 2023 21:06 ET
|
Nkarta, Inc.
SOUTH SAN FRANCISCO, Calif., April 12, 2023 (GLOBE NEWSWIRE) -- Nkarta, Inc. (Nasdaq: NKTX), a biopharmaceutical company developing engineered natural killer (NK) cell therapies to treat cancer,...
Nkarta Announces Departure of Chief Financial & Business Officer
March 30, 2023 16:01 ET
|
Nkarta, Inc.
Clinical updates on track for NKX101 in first half of 2023 and NKX019 in full year 2023 SOUTH SAN FRANCISCO, Calif., March 30, 2023 (GLOBE NEWSWIRE) -- Nkarta, Inc. (Nasdaq: NKTX), a clinical-stage...
Nkarta Reports Fourth Quarter and Full Year 2022 Financial Results and Corporate Highlights
March 16, 2023 16:01 ET
|
Nkarta, Inc.
Clinical updates on track for NKX101 in first half of 2023 and NKX019 in full year 20232022 year-end cash and cash equivalents of $354.9 millionCash runway anticipated to fund operations into 2025 ...
Nkarta to Participate at Upcoming Investor Conferences
February 09, 2023 08:02 ET
|
Nkarta, Inc.
SOUTH SAN FRANCISCO, Calif., Feb. 09, 2023 (GLOBE NEWSWIRE) -- Nkarta, Inc. (Nasdaq: NKTX), a biopharmaceutical company developing engineered natural killer (NK) cell therapies to treat cancer,...
Nkarta Promotes David R. Shook, M.D., to Chief Medical Officer
January 09, 2023 16:30 ET
|
Nkarta, Inc.
SOUTH SAN FRANCISCO, Calif., Jan. 09, 2023 (GLOBE NEWSWIRE) -- Nkarta, Inc. (Nasdaq: NKTX), a clinical-stage biopharmaceutical company developing engineered natural killer (NK) cell therapies to...
Nkarta Announces Updated Clinical Data on Anti-CD19 Allogeneic CAR-NK Cell Therapy NKX019 for Patients with Relapsed or Refractory Non-Hodgkin Lymphoma
December 05, 2022 07:02 ET
|
Nkarta, Inc.
7 of 10 patients treated with NKX019 monotherapy at 1 billion and 1.5 billion CAR NK cells per dose achieved complete response (70% CR rate)5 CRs achieved across all dose levels after a single cycle...
Nkarta to Host Conference Call to Discuss Updated Clinical Data from NKX019 NK Cell Therapy Program
December 02, 2022 16:02 ET
|
Nkarta, Inc.
SOUTH SAN FRANCISCO, Calif., Dec. 02, 2022 (GLOBE NEWSWIRE) -- Nkarta, Inc. (Nasdaq: NKTX), a biopharmaceutical company developing engineered natural killer (NK) cell therapies to treat cancer,...
Nkarta Reports Third Quarter 2022 Financial Results and Corporate Highlights
November 09, 2022 16:02 ET
|
Nkarta, Inc.
NKX101 and NKX019 allogeneic cell therapy programs continue to advance following initial clinical data reported in April 2022NKX019 Phase 1 clinical trial recently opened dose expansion cohortsNKX019...
Nkarta Presents Data Supporting Engineered NK Cell Based Combination Therapies and Next Generation Commercial-Scale Manufacturing Platform at SITC 37th Annual Meeting
November 07, 2022 08:52 ET
|
Nkarta, Inc.
Improved Anti-Tumor Activity Demonstrated by the Combination of NKX019 and a CD20-directed Monoclonal Antibody in Preclinical Models Pulsed Stimulation of NK Cells Derived from Peripheral Blood of...